Vol 51 No 12

Over the past year, the FDA approved a multitude of new treatments and devices for use in urology practice.

"The conversion factor is slated to undergo a reduction of approximately 3.37% for 2024, decreasing from $33.89 in 2023 to $32.74," write Jonathan Rubenstein, MD, and Mark Painter.

"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.

"Keeping up-to-date is challenging, and rapid progress that is now occurring in our field is truly amazing," writes Michael S. Cookson, MD, MMHC, FACS.

"The end of the year presents a good opportunity to regroup, close out 2023 in the strongest position possible, and ready yourself for 2024," writes Jeff Witz, CFP.

“It was interesting to find that when Black and White men were provided equal access to the same therapies, given at the same dosage and monitored in the same setting, disparities in outcomes were eliminated," says Jun Gong, MD.

“As private equity firms increasingly engage in urology, key stakeholders, including policymakers and urologists, need to ensure that the quality of care is not compromised with the structural changes implemented after acquisition," write the authors.

"Our data show no evidence of benefit from selenium and evidence of harm from vitamin E—a compound readily available over the counter," the authors write.

At 3 months following treatment, 50% of men who received CCH injections reported being “very satisfied” overall, compared with 21% of patients in the surgery group.